Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global oral solid dosage contract manufacturing market size was valued at approximately USD 75.5 billion in 2024. The market is projected to grow from USD 80.3 billion in 2025 to USD 117.2 billion by 2031, exhibiting a compound annual growth rate (CAGR) of around 6.5% during the forecast period.
Oral solid dosage (OSD) contract manufacturing involves outsourcing the production of solid-form pharmaceuticals, such as tablets, capsules, powders, and granules, to specialized third-party organizations. This business model allows pharmaceutical companies to leverage external expertise, advanced technologies, and scalable production capacity without major capital investment, which is crucial for managing the complex and regulated process of drug development and commercialization.
This market's robust growth is primarily driven by the pharmaceutical industry's strategic focus on cost optimization and core competencies. Because developing manufacturing facilities in-house is incredibly capital-intensive, companies increasingly turn to Contract Development and Manufacturing Organizations (CDMOs). Furthermore, the rising demand for generic medicines, combined with the expiration of blockbuster drug patents, creates a significant pipeline of products requiring efficient manufacturing. The top five players, including Catalent, Lonza Group, and Piramal Pharma Solutions, held a significant combined market share in 2024, highlighting a competitive but concentrated landscape.
Rising Pharmaceutical Outsourcing and Cost Optimization
Pharmaceutical companies are increasingly focusing on their core competencies of R&D and marketing, leading to a strategic shift towards outsourcing manufacturing activities. The high capital investment required for building and maintaining oral solid dosage (OSD) manufacturing facilities, coupled with stringent regulatory requirements, makes contract manufacturing an attractive option. This trend is driven by the need for cost containment and operational flexibility, allowing innovators to accelerate time-to-market for new drugs.
Growing Prevalence of Chronic Diseases and Aging Population
The global increase in chronic conditions such as cardiovascular diseases, diabetes, and neurological disorders necessitates long-term medication, predominantly in oral solid forms like tablets and capsules. An aging global population further amplifies the demand for affordable and accessible medicines. This sustained demand creates a stable and growing market for OSD contract development and manufacturing organizations (CDMOs) to support the production of both branded and generic pharmaceuticals.
➤ Technological innovations in drug delivery systems, such as controlled-release formulations and orally disintegrating tablets, are expanding the capabilities and value proposition of specialized OSD contract manufacturers.
Furthermore, the expansion of the generic drug market post-patent expirations of blockbuster drugs generates substantial volume-based demand for cost-effective OSD manufacturing, which CDMOs are strategically positioned to fulfill.
MARKET CHALLENGES
Stringent Regulatory Hurdles and Compliance
OSD contract manufacturers operate in a highly regulated environment governed by agencies like the US FDA, EMA, and others. Maintaining compliance with current Good Manufacturing Practices (cGMP) and navigating the complexities of regulatory approvals for different markets requires significant investment in quality systems and expertise. Any compliance failure can lead to costly recalls, plant shutdowns, and reputational damage, posing a constant challenge.
Other Challenges
Supply Chain Complexity and API Sourcing
The reliability of the supply chain for active pharmaceutical ingredients (APIs) and excipients is critical. Disruptions, quality inconsistencies, or price volatility of raw materials can directly impact production schedules and product quality, creating significant operational challenges for CDMOs.
Intense Price Competition and Margin Pressure
The market is highly competitive, with numerous players vying for contracts. This often leads to price-based competition, squeezing profit margins for CDMOs. Clients demand high-quality manufacturing at the lowest possible cost, forcing manufacturers to continuously optimize their operations for efficiency.
High Capital Investment for Advanced Technologies
Implementing and maintaining state-of-the-art manufacturing technologies, such as continuous manufacturing and advanced containment systems, requires substantial capital expenditure. This high barrier to entry can restrain the growth of smaller or mid-sized contract manufacturers who may lack the financial resources to invest in these capabilities, limiting their ability to compete for high-value contracts.
Intellectual Property and Confidentiality Concerns
Pharmaceutical companies may be hesitant to outsource the manufacturing of their proprietary formulations due to concerns about protecting intellectual property (IP) and maintaining confidentiality. Establishing robust IP protection agreements and secure data management practices is essential, but residual apprehension can sometimes act as a restraint on outsourcing decisions.
Expansion in Emerging Markets
Rising healthcare expenditure, improving regulatory frameworks, and growing generic drug consumption in emerging economies across Asia-Pacific and Latin America present significant growth opportunities. OSD CDMOs can capitalize on this by establishing local manufacturing presence or forming strategic partnerships to serve these rapidly expanding markets.
Specialization in High-Potency APIs (HPAPIs) and Complex Formulations
There is increasing demand for contract manufacturing services for highly potent compounds used in oncology and other specialized therapies. CDMOs that invest in the necessary containment infrastructure and expertise to handle these complex and high-value products can command premium pricing and secure long-term partnerships with biopharma companies.
Adoption of Continuous Manufacturing and Industry 4.0
The transition from traditional batch processing to continuous manufacturing offers advantages in efficiency, quality control, and scalability. CDMOs that lead in adopting these advanced manufacturing technologies, along with data analytics and automation (Industry 4.0), can differentiate themselves and attract clients seeking innovative and efficient production solutions.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights | |
| By Type |
|
Tablets represent the leading segment, driven by their patient-friendly characteristics such as dose precision, ease of swallowing with various coating technologies, and exceptional stability which simplifies logistics. This format benefits from extensive manufacturing expertise and is preferred for a vast array of therapeutic areas, making it the cornerstone of the market. Capsules are also highly significant, favored for their ability to mask unpleasant tastes and for the faster absorption of liquid or semi-solid fill formulations compared to compressed tablets. | |
| By Application |
|
Big Pharma is the dominant consumer of contract manufacturing services, primarily leveraging these partnerships to optimize internal capacity, manage complex supply chains, and reduce time-to-market for new drug launches. These collaborations allow large pharmaceutical companies to focus their substantial resources on core R&D and marketing activities. Concurrently, the Generics segment is a major growth driver, relying heavily on CMOs for cost-effective, high-volume production to compete in fast-paced markets following patent expirations. | |
| By End User |
|
Pharmaceutical Companies are the most significant end-user group, utilizing CMOs across the entire drug development lifecycle from clinical trial material supply to commercial manufacturing. The reliance on external manufacturers is fueled by the need for specialized technology platforms and flexible production scaling. Biopharmaceutical companies are an increasingly important segment, often outsourcing the formulation of small molecule drugs that complement their biologic pipelines, requiring partners with stringent quality control to match their high standards. | |
| By Service Type |
|
Manufacturing is the core and leading service offering, encompassing the large-scale, cGMP-compliant production of oral solid dosage forms. This segment’s dominance is underpinned by the capital-intensive nature of establishing and maintaining production facilities. Clients seek partners with proven expertise in ensuring batch-to-batch consistency and regulatory compliance. Formulation Development is a critical high-value service, especially for products with poor solubility or complex release profiles, requiring sophisticated scientific expertise to achieve bioavailability targets. | |
| By Dosage Form Complexity |
|
Standard Dosage Forms | Standard Dosage Forms constitute the bulk of the market volume, characterized by immediate-release tablets and capsules that are relatively straightforward to manufacture. However, the most significant value growth is observed in Controlled-Release Dosage Forms, which offer enhanced therapeutic outcomes through delayed or sustained drug release, requiring advanced technological capabilities and specialized equipment from CMOs. The market for High-Potency Products is also expanding, demanding sophisticated containment and handling protocols to ensure operator safety and product integrity. |
A Market Characterized by Scale, Expertise, and Global Reach
The global Oral Solid Dosage (OSD) Contract Manufacturing market features a competitive environment dominated by a few large-scale players that command a significant portion of the revenue. Companies like Catalent, Lonza Group (through its Capsugel division), and Piramal Pharma Solutions lead the market, benefiting from extensive manufacturing capacity, advanced technological capabilities such as continuous manufacturing and specialized coating techniques, and a global network of facilities that ensures supply chain resilience. These top players primarily serve the demanding requirements of 'Big Pharma' clients, offering end-to-end services from formulation development and clinical trial manufacturing to commercial-scale production. The global top five players collectively held a substantial market share in terms of revenue in 2024, underscoring the concentrated nature of the high-volume segment of the market.
Beyond the dominant leaders, the landscape includes a robust segment of significant niche and regional players that contribute to market diversity. Companies such as Aenova, Jubilant, and Recipharm offer strong capabilities and compete effectively, often focusing on specific technologies like softgel capsules or serving particular geographic regions. Other key participants like Famar, Boehringer Ingelheim's contract manufacturing arm, and Fareva Holding bring specialized expertise and reliable production quality. Furthermore, a range of established companies including Nipro Pharma, Sopharma, and NextPharma cater to generics manufacturers and specialty pharma companies, providing essential manufacturing services and contributing to the overall capacity and flexibility of the global OSD contract manufacturing industry.
List of Key Oral Solid Dosage Contract Manufacturing Companies ProfiledCatalent
Piramal Pharma Solutions
Aenova
Jubilant
Famar
Boehringer Ingelheim
Fareva Holding
AbbVie Contract Manufacturing
Nipro Pharma
Sopharma
NextPharma
Dishman
The global Oral Solid Dosage (OSD) contract manufacturing market is demonstrating significant growth, with the industry valued at million USD in 2024 and projected to reach a multi-million dollar valuation by 2031. A key trend underpinning this expansion is the strategic shift among pharmaceutical companies towards outsourcing manufacturing operations. This allows them to focus internal resources on core competencies like research and development while leveraging the specialized expertise, advanced technologies, and cost-efficiencies offered by contract manufacturing organizations (CMOs). The market is expected to grow at a steady Compound Annual Growth Rate (CAGR) throughout the forecast period, driven by this fundamental industry dynamic.
Other TrendsDominance and Growth of the Tablets Segment
Within the OSD market, the tablets segment is a dominant and rapidly growing category, projected to reach million USD by 2031 with a substantial CAGR over the next several years. Tablets remain the most preferred dosage form due to their patient compliance, stability, and ease of manufacturing. CMOs are investing in advanced technologies for tablet production, including continuous manufacturing and highly potent compound handling capabilities, to meet the diverse needs of their clients across different therapeutic areas.
Consolidation and Competitive LandscapeThe global OSD contract manufacturing landscape is characterized by the presence of established international players and is experiencing a trend of consolidation. In 2024, the top five companies, which include leaders such as Catalent, Lonza Group (Capsugel), and Piramal Pharma Solutions, held a significant combined market share. Mergers and acquisitions are a common strategy for these companies to expand their geographic footprint, service offerings, and technological capabilities. This consolidation trend is intensifying competition and driving CMOs to differentiate themselves through specialized services and superior quality standards.
Geographical Market Dynamics
Regionally, North America, particularly the United States with an estimated market size of million USD in 2024, represents a major hub for OSD contract manufacturing due to its large pharmaceutical industry and stringent regulatory environment. However, the Asia-Pacific region, led by China which is projected to reach million USD, is emerging as a high-growth market. This growth is fueled by lower manufacturing costs, a skilled workforce, and increasing investments in healthcare infrastructure, making it an attractive destination for outsourcing.
Diverse Client Base: Big Pharma and Generics
The market serves a diverse client base segmented into Big Pharma, generics, and specialty/midsize companies. Big Pharma companies continue to be major clients, outsourcing complex formulations to manage their extensive pipelines. Simultaneously, the generics segment represents a significant and steady source of demand for high-volume, cost-effective manufacturing. This dual demand structure ensures a stable and growing market for OSD CMOs, who must be adaptable to the different requirements of these client types.
Regional Analysis: Oral Solid Dosage Contract Manufacturing MarketEurope
Europe represents a highly mature and sophisticated market for OSD contract manufacturing, characterized by a harmonized yet stringent regulatory framework under the European Medicines Agency (EMA). The region benefits from a strong tradition of pharmaceutical innovation and a network of highly capable CDMOs, particularly in countries like Germany, Switzerland, Italy, and the UK. These providers excel in manufacturing complex generics, value-added formulations, and handling the requirements of the Falsified Medicines Directive. The market dynamics are influenced by cost-containment pressures from national healthcare systems, which drive pharmaceutical companies to outsource manufacturing to achieve efficiencies. European CDMOs are also leaders in environmental sustainability, often incorporating green chemistry principles into their processes. The proximity to a large patient population and a well-established clinical trials infrastructure further solidifies Europe's position as a key strategic hub for OSD outsourcing.
Asia-Pacific
The Asia-Pacific region is the fastest-growing market for OSD contract manufacturing, driven primarily by cost advantages, expanding pharmaceutical markets, and significant government support for the pharmaceutical sector. Countries like India and China are global powerhouses, offering substantial cost efficiencies and massive production scale capabilities for generic medicines. Japan and South Korea contribute with their high-quality standards and expertise in innovative formulations. The growth is fueled by increasing healthcare access, a rising burden of chronic diseases, and the expansion of local pharmaceutical companies into international markets. While cost is a major driver, leading APAC CDMOs are rapidly advancing their regulatory capabilities and investing in upgraded facilities to meet international Good Manufacturing Practice (GMP) standards, making them increasingly attractive partners for global pharmaceutical companies seeking to optimize their supply chains.
South America
The OSD contract manufacturing market in South America is an emerging landscape, marked by growing local pharmaceutical production and increasing regulatory harmonization efforts. Brazil is the dominant player in the region, with a large domestic market and government policies that encourage local manufacturing. Argentina and Mexico also have developing capabilities. The market growth is primarily driven by the need to improve access to affordable medicines and reduce dependency on imports. However, the market faces challenges such as economic volatility and varying regulatory requirements across countries. CDMOs in the region are gradually building expertise and capacity, often focusing on serving local and regional markets with generic medicines and increasingly seeking partnerships with international firms to enhance their technological and quality standards.
Middle East & Africa
The Middle East and Africa region presents a diverse and developing market for OSD contract manufacturing. Growth is largely driven by government initiatives aimed at boosting local pharmaceutical production to enhance medicine security and reduce import reliance, particularly in Gulf Cooperation Council countries like Saudi Arabia and the UAE. South Africa remains the most developed market in Sub-Saharan Africa. The region's CDMO landscape is characterized by a focus on generic medicines, with growing investments in manufacturing infrastructure. Challenges include fragmented markets, regulatory heterogeneity, and infrastructure gaps in some areas. However, the potential for growth is significant, fueled by rising populations, increasing healthcare expenditure, and strategic efforts to position the region as a pharmaceutical manufacturing hub for both local consumption and export to neighboring markets.
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global oral solid dosage contract manufacturing market was valued at USD 75.5 billion in 2024 and is expected to reach USD 117.2 billion by 2031.
-> Key players include Catalent, Lonza Group, Piramal Pharma Solutions, Jubilant, and Aenova, among others.
-> The market is projected to grow at a CAGR of 6.5% during 2025-2031.
-> North America currently leads the market, while Asia-Pacific shows the highest growth potential.
-> Key segments include tablets, capsules, and powders & granules manufacturing services.
Our Clients
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates